Jiangsu Recbio Technology Reports Interim Analysis Data from the Study of REC610 for Shingles Conducted in the Philippines
Shots:
- The FIH study evaluates the safety and efficacy of REC610 (novel adjuvanted recombinant vaccine) vs GSK’s Shingrix for the treatment of shingles in the Philippines
- The analysis revealed a positive safety and tolerability profile in healthy individuals of 40yrs. & above after two doses of REC610 vaccination. REC610 induced robust gE-specific humoral and cellular immune responses, peaking 30 days after the second dose. The responses were comparable to the Shingrix group, with the REC610 group showing higher immune response
- The company plans to conduct P-I study to assess REC610's safety, tolerability, and immunogenicity in healthy subjects (n=180) 40yrs. and above in Mainland China in near the term
Ref: PR Newswire | Image: Jiangsu Recbio Technology
Related News:- Jiangsu Recbio Technology Reports P-II Study Results of Two-Component COVID-19 Vaccine ReCOV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
